爱尔眼科(300015) - 2015 Q4 - 年度业绩

Financial Performance - Total revenue for 2015 reached CNY 3,165,580,471.34, representing a 31.79% increase compared to CNY 2,402,047,616.93 in 2014[4] - Operating profit was CNY 599,466,055.13, up 39.62% from CNY 429,350,766.46 in the previous year[4] - Net profit attributable to shareholders was CNY 427,143,581.98, reflecting a 38.15% growth from CNY 309,186,277.78 in 2014[4] - Basic earnings per share increased to CNY 0.44, a rise of 41.94% compared to CNY 0.31 in the prior year[4] Return on Investment - Return on equity (ROE) was 19.70%, an increase of 2.23 percentage points from 17.47% in 2014[4] Assets and Equity - Total assets at the end of the reporting period were CNY 3,256,058,140.88, a 27.67% increase from CNY 2,550,430,405.25 at the beginning of the year[4] - Equity attributable to shareholders rose to CNY 2,394,921,525.99, marking a 20.44% increase from CNY 1,988,433,321.96[4] - The total share capital increased by 50.63% to CNY 985,560,192.00 due to capital reserve conversion and stock option exercises[6] - Net asset value per share decreased by 20.04% to CNY 2.43 from CNY 3.039[4] Reporting Accuracy - The company confirmed that there were no discrepancies between the reported results and the previously announced performance forecast[7]